Entry

D11876                      Drug

Name

Efgartigimod alfa (USAN/INN);
Efgartigimod alfa (genetical recombination) (JAN);
Efgartigimod alfa-fcab;
Vyvgart (TN)

Product

VYVGART (argenx US)

Formula

C2310H3554N602O692S14

Exact mass

51247.7506

Mol weight

51279.464

Sequence

DKTHTCPPCP APELLGGPSV FLFPPKPKDT LYITREPEVT CVVVDVSHED PEVKFNWYVD
GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK
GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS
DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALKFHYTQKS LSLSPGK
(Disulfide bridge: 6-6', 9-9', 41-101, 147-205, 41'-101', 147'-205')

Type

Peptide

Remark

Therapeutic category:

6399

Product:

D11876<JP/US>

Efficacy

Autoimmune disease treatment

Disease

Generalized myasthenia gravis (AChR antibody positive) [DS:H01594]

Comment

Treatment of IgG-driven autoimmune diseases

Target

FCGRT [HSA:2217] [KO:K24019]

Interaction

Brite

Therapeutic category of drugs in Japan [BR:br08301]
6  Agents against pathologic organisms and parasites
  63  Biological preparations
   639  Miscellaneous
    6399  Others
     D11876  Efgartigimod alfa (USAN/INN); Efgartigimod alfa (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Not elsewhere classified
  Organismal systems
   Immune system
    FCGRT
     D11876  Efgartigimod alfa (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
  D11876
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
  D11876
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
  D11876
Pharmacogenomic biomarkers [br08341.html]
Germline mutations in genetic disorder treatments
  D11876

Other DBs

CAS:	1821402-21-4